6,7-dimethoxy-3-(3-methoxyphenyl)isoquinolin-1-amine induces mitotic arrest and apoptotic cell death through the activation of spindle assembly checkpoint in human cervical cancer cells

Carcinogenesis

Volumn 34, Issue 8, 2013, Pages 1852-1860

  Chung, Kyung Sook ^a   Choi, Hye Eun ^a   Shin, Ji Sun ^a,b   Cho, Young Wuk ^b   Choi, Jung Hye ^a   Cho, Won Jea ^c   Lee, Kyung Tae ^a  

^a Kyung Hee University   (South Korea)

^b Kyung Hee University Hospital   (South Korea)

^c Chonnam National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIMETHOXY 3 (3 METHOXYPHENYL)ISOQUINOLIN 1 AMINE; ALPHA TUBULIN; ANTINEOPLASTIC AGENT; BUB1 RELATED PROTEIN; CELL CYCLE PROTEIN 20; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; HISTONE H3; PROTEIN MAD2; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CONTROLLED STUDY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; M PHASE CELL CYCLE CHECKPOINT; MICROTUBULE; MITOSIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN POLYMERIZATION; TUMOR GROWTH; UTERINE CERVIX CANCER;

EID: 84881538710     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt133     Document Type: Article

References (44)

1. Zhou, J. et al. (2005) Targeting microtubules for cancer chemotherapy. Curr. Med. Chem. Anticancer Agents, 5, 65-71.
2. Pasquier, E., et al. (2008) Microtubules: a dynamic target in cancer therapy. IUBMB Life, 60, 165-170.
3. McGrogan, B.T., et al. (2008) Taxanes, microtubules and chemoresistant breast cancer. Biochim. Biophys. Acta, 1785, 96-132.
4. Islam, M.N., et al. (2004) Microtubulin binding sites as target for developing anticancer agents. Mini Rev. Med. Chem., 4, 1077-1104.
5. Tan, A.L., et al. (2005) Essential tension and constructive destruction: the spindle checkpoint and its regulatory links with mitotic exit. Biochem. J., 386, 1-13.
6. Yu, H. (2007) Cdc20: a WD40 activator for a cell cycle degradation machine. Mol. Cell, 27, 3-16.
7. van Leuken, R., et al. (2008) To cell cycle, swing the APC/C. Biochim. Biophys. Acta, 1786, 49-59.
8. Yu, H. (2006) Structural activation of Mad2 in the mitotic spindle checkpoint: the two-state Mad2 model versus the Mad2 template model. J. Cell Biol., 173, 153-157.
9. Jeong, H.W., et al. (2009) Berberine suppresses proinflammatory responses through AMPK activation in macrophages. Am. J. Physiol. Endocrinol. Metab., 296, E955-E964.
10. Iwasa, K., et al. (2001) Simple isoquinoline and benzylisoquinoline alkaloids as potential antimicrobial, antimalarial, cytotoxic, and anti-HIV agents. Bioorg. Med. Chem., 9, 2871-2884.
11. Khadka, D.B., et al. (2011) 3-Arylisoquinolines as novel topoisomerase I inhibitors. Bioorg. Med. Chem., 19, 724-734.
12. Won, S.J., et al. (2010) CWJ-081, a novel 3-arylisoquinoline derivative, induces apoptosis in human leukemia HL-60 cells partially involves reactive oxygen species through c-Jun NH2-terminal kinase pathway. Bioorg. Med. Chem. Lett., 20, 6447-6451.
13. Cho, W.J., et al. (2002) Molecular modeling of 3-arylisoquinoline antitumor agents active against A-549. A comparative molecular field analysis study. Bioorg. Med. Chem., 10, 2953-2961.
14. Pachon, G., et al. (2007) Anticancer effect of a new benzophenanthridine isolated from Zanthoxylum madagascariense (Rutaceline). In Vivo, 21, 417-422.
15. Guo, L., et al. (2007) Inhibition of topoisomerase IIalpha and G2 cell cycle arrest by NK314, a novel benzo[c]phenanthridine currently in clinical trials. Mol. Cancer Ther., 6, 1501-1508.
16. Vogt, A., et al. (2005) The benzo[c]phenanthridine alkaloid, sanguinarine, is a selective, cell-active inhibitor of mitogen-activated protein kinase phosphatase-1. J. Biol. Chem., 280, 19078-19086.
17. Yang, S.H., et al. (2010) Development of 3-aryl-1-isoquinolinamines as potent antitumor agents based on CoMFA. Eur. J. Med. Chem., 45, 5493-5497.
18. Doherty, S.C., et al. (2003) Cell cycle checkpoint function in bladder cancer. J. Natl Cancer Inst., 95, 1859-1868.
19. Koopman, G., et al. (1994) Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood, 84, 1415-1420.
20. Dethlefsen, L.A., et al. (1968) Analysis of tumor growth curves. J. Natl Cancer Inst., 40, 389-405.
21. Le Breton, M., et al. (2005) Translational control during mitosis. Biochimie, 87, 805-811.
22. Draviam, V.M., et al. (2007) A functional genomic screen identifies a role for TAO1 kinase in spindle-checkpoint signalling. Nat. Cell Biol., 9, 556-564.
23. Kang, J., et al. (2009) Kinase signaling in the spindle checkpoint. J. Biol. Chem., 284, 15359-15363.
24. Weaver, B.A., et al. (2005) Decoding the links between mitosis, cancer, and chemotherapy: the mitotic checkpoint, adaptation, and cell death. Cancer Cell, 8, 7-12.
25. Musacchio, A., et al. (2007) The spindle-assembly checkpoint in space and time. Nat. Rev. Mol. Cell Biol., 8, 379-393.
26. Shin, K.D., et al. (2008) KRIBB3, a novel microtubule inhibitor, induces mitotic arrest and apoptosis in human cancer cells. Biochem. Pharmacol., 75, 383-394.
27. Cho, W.J., et al. (2007) Design, docking, and synthesis of novel indeno[1,2-c]isoquinolines for the development of antitumor agents as topoisomerase I inhibitors. Bioorg. Med. Chem. Lett., 17, 3531-3534.
28. Van, H.T., et al. (2009) Structural modification of 3-arylisoquinolines to isoindolo[2,1-b]isoquinolinones for the development of novel topoisomerase 1 inhibitors with molecular docking study. Bioorg. Med. Chem. Lett., 19, 2551-2554.
29. Lee, S.H., et al. (2009) Molecular design, synthesis and docking study of benz[b]oxepines and 12-oxobenzo[c]phenanthridinones as topoisomerase 1 inhibitors. Bioorg. Med. Chem. Lett., 19, 2444-2447.
30. Chen, Y.C., et al. (2007) Quinolone analogue inhibits tubulin polymerization and induces apoptosis via Cdk1-involved signaling pathways. Biochem. Pharmacol., 74, 10-19.
31. Jakowlew, S.B. (2006) Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev., 25, 435-457.
32. Allan, L.A., et al. (2007) Phosphorylation of caspase-9 by CDK1/cyclin B1 protects mitotic cells against apoptosis. Mol. Cell, 26, 301-310.
33. Castedo, M., et al. (2002) Cyclin-dependent kinase-1: linking apoptosis to cell cycle and mitotic catastrophe. Cell Death Differ., 9, 1287-1293.
34. Lolli, G., et al. (2005) CAK-Cyclin-dependent Activating Kinase: a key kinase in cell cycle control and a target for drugs?. Cell Cycle, 4, 572-577.
35. Malumbres, M., et al. (2005) Mammalian cyclin-dependent kinases. Trends Biochem. Sci., 30, 630-641.
36. Nitta, M., et al. (2004) Spindle checkpoint function is required for mitotic catastrophe induced by DNA-damaging agents. Oncogene, 23, 6548-6558.
37. Wu, Y.C., et al. (2008) Requirement of a functional spindle checkpoint for arsenite-induced apoptosis. J. Cell. Biochem., 105, 678-687.
38. Altmann, K.H., et al. (2007) Anticancer drugs from nature-natural products as a unique source of new microtubule-stabilizing agents. Nat. Prod. Rep., 24, 327-357.
39. Honore, S., et al. (2005) Understanding microtubule dynamics for improved cancer therapy. Cell. Mol. Life Sci., 62, 3039-3056.
40. Vakifahmetoglu, H., et al. (2008) Death through a tragedy: mitotic catastrophe. Cell Death Differ., 15, 1153-1162.
41. Blagosklonny, M.V. (2007) Mitotic arrest and cell fate: why and how mitotic inhibition of transcription drives mutually exclusive events. Cell Cycle, 6, 70-74.
42. Castedo, M., et al. (2004) Mitotic catastrophe: a special case of apoptosis. J. Soc. Biol., 198, 97-103.
43. Lee, E.A., et al. (2004) Inactivation of the mitotic checkpoint as a determinant of the efficacy of microtubule-targeted drugs in killing human cancer cells. Mol. Cancer Ther., 3, 661-669.
44. Kang, C., et al. (2012) The natively disordered loop of Bcl-2 undergoes phosphorylation-dependent conformational change and interacts with Pin1. PLoS One, 7, e52047.